CTI Molecular Imaging posts double-digit gains in FY03

Revenue growth across all of its product and service segments propelled CTI Molecular Imaging Inc. to higher revenue totals in FY03, ending September 30. Revenues totaled $362.2 million, compared with $258.4 million in FY02.

 CPS Innovations, CTI's business units which develops and manufactures the company's PET and PET-CT systems, contributed revenues of $172 million in FY03, compared with $151.3 million in FY02. Net income rose to $20.6 million in FY03, compared with a net loss of $3.4 million in FY02. CTI also noted that it is "comfortable" with revenue projections in the range of $435 million to $445 million in FY04.

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Trimed Popup
Trimed Popup